The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
The hemostatic effects of recombinant human erythropoietin (rHuEP) were investigated in 20 patients with end-stage renal disease (thirteen on hemodialysis, seven without dialysis) receiving this hormone. We studied their hemograms and coagulation profiles before and at 1 month after initiation of rHuEP therapy. One month after rHuEP administration, improvement in anemia (16/20, 80%) and shortening of bleeding time (17/19, 89.5%) were observed. Shortening or correction of bleeding time was achieved in three patients without any increase of the hemoglobin level. This means that factors other than the increased hematocrit level might contribute to shortening bleeding time in uremic patients receiving rHuEP treatment. The platelet count, prothrombin time, partial thromboplastin time, and fibrinogen level did not change over the course of rHuEP therapy. Thrombosis of vascular access was not observed, and heparin doses were not increased in this short-term period. A significant decrease was found in the plasminogen level, from 108.5% to 88.2% (p less than 0.05), in uremic patients on hemodialysis. The antithrombin III level also decreased, from 98.8% to 89.8% (p less than 0.05), and its level dropped to below normal ranges in six of thirteen patients (46%) on hemodialysis after treatment with rHuEP. No significant change was noted in the levels of antithrombin III, plasminogen, and alpha 2-antiplasmin in uremic patients not receiving dialysis. These results suggest that rHuEP administration induces increased extracorporeal dialyzer clotting and consumption coagulopathy, and that this extracorporeal consumption coagulopathy may play a role in the genesis of thrombotic complications.
Tsao
C J
CJ
Department of Medicine, College of Medicine, National Cheng-Kung University, Tainan, Taiwan, R.O.C.
Kao
R H
RH
Cheng
T Y
TY
Huang
C C
CC
Chang
S L
SL
Lee
F N
FN
D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000990:Antithrombin III / Q000032:analysis; D001760:Bleeding Time; D001780:Blood Coagulation Tests; D002908:Chronic Disease; D004921:Erythropoietin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D010958:Plasminogen / Q000032:analysis; D010976:Platelet Count / Q000187:drug effects; D011516:Prothrombin / Q000032:analysis; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000150:complications / Q000628:therapy; D000979:alpha-2-Antiplasmin / Q000032:analysis
D006454:Hemoglobins; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; D000979:alpha-2-Antiplasmin; C045879:prothrombin fragment 1.2; D004921:Erythropoietin; D000990:Antithrombin III; D011516:Prothrombin; D010958:Plasminogen